...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >PARP1 is required for chromosomal translocations.
【24h】

PARP1 is required for chromosomal translocations.

机译:染色体易位需要PARP1。

获取原文
获取原文并翻译 | 示例

摘要

Chromosomal translocations are common contributors to malignancy, yet little is known about the precise molecular mechanisms by which they are generated. Sequencing translocation junctions in acute leukemias revealed that the translocations were likely mediated by a DNA double-strand break repair pathway termed nonhomologous end-joining (NHEJ). There are major 2 types of NHEJ: (1) the classical pathway initiated by the Ku complex, and (2) the alternative pathway initiated by poly ADP-ribose polymerase 1 (PARP1). Recent reports suggest that classical NHEJ repair components repress translocations, whereas alternative NHEJ components were required for translocations. The rate-limiting step for initiation of alternative NHEJ is the displacement of the Ku complex by PARP1. Therefore, we asked whether PARP1 inhibition could prevent chromosomal translocations in 3 translocation reporter systems. We found that 2 PARP1 inhibitors or repression of PARP1 protein expression strongly repressed chromosomal translocations, implying that PARP1 is essential for this process. Finally, PARP1 inhibition also reduced both ionizing radiation-generated and VP16-generated translocations in 2 cell lines. These data define PARP1 as a critical mediator of chromosomal translocations and raise the possibility that oncogenic translocations occurring after high-dose chemotherapy or radiation could be prevented by treatment with a clinically available PARP1 inhibitor.
机译:染色体易位是导致恶性肿瘤的常见原因,但对其产生的确切分子机制知之甚少。对急性白血病中的易位连接进行测序表明,该易位可能由称为非同源末端连接(NHEJ)的DNA双链断裂修复途径介导。 NHEJ主要有两种类型:(1)由Ku复合物引发的经典途径,以及(2)由聚ADP-核糖聚合酶1(PARP1)引发的替代途径。最近的报告表明,经典的NHEJ修复组件可抑制易位,而替代的NHEJ组件则需要易位。引发替代NHEJ的速率限制步骤是KARP配合物被PARP1取代。因此,我们问PARP1抑制是否可以阻止3个易位报告系统中的染色体易位。我们发现2种PARP1抑制剂或PARP1蛋白表达的抑制强烈抑制了染色体易位,这暗示PARP1对于此过程至关重要。最后,PARP1抑制还减少了两个细胞系中电离辐射产生的和VP16产生的易位。这些数据将PARP1定义为染色体易位的关键介体,并提出了通过用临床上可用的PARP1抑制剂治疗可预防大剂量化疗或放疗后发生的致癌性易位的可能性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号